ALK and non-small cell lung carcinoma: Together, these results show that cell sensitivity to the ALK-TKIs alectinib or brigatinib is enhanced by cotreatment with afatinib in ALK-rearranged NSCLC cell lines with a mesenchymal-like phenotype, but not in those with an epithelial-like phenotype.